Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $501
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Andrew Mok maintains an Overweight rating on Elevance Health but lowers the price target from $622 to $501.
October 22, 2024 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Andrew Mok maintains an Overweight rating on Elevance Health but lowers the price target from $622 to $501, indicating a more cautious outlook.
The reduction in the price target from $622 to $501 suggests a less optimistic view on Elevance Health's future performance, which could lead to a short-term negative impact on the stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100